Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Paclitaxel in Advanced Head and Neck Cancer
NCT01024101Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2004
- Primary completion
- Dec 2005
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection in head and neck cancer (HNC), sponsored by Bristol Myers Squibb. Primary endpoints: Response Rate and Incidence and severity of adverse events and laboratory test abnormalities. Started Jan 2004; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT01024101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024101.